Renal Cancer - Results from #1640

Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. February 4, 2022

Improving accuracy, reliability, and efficiency of the RENAL nephrometry score with 3D reconstructed virtual imaging. February 3, 2022

Decreased CDKL2 Expression in Clear Cell Renal Cell Carcinoma Predicts Worse Overall Survival. February 3, 2022

The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis. February 2, 2022

Decreased Expression of ACADSB Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma. February 2, 2022

The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma. February 1, 2022

Utilizing head-mounted eye trackers to analyze patterns and decision-making strategies of 3D virtual modelling platform (IRIS™) during preoperative planning for renal cancer surgeries. February 1, 2022

Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma. January 31, 2022

Prognostic and Clinicopathological Correlations of Pretreatment Prognostic Nutritional Index in Renal Cell Carcinoma: A Meta-Analysis. January 31, 2022

MicroRNA-155-5p targets NR3C2 to promote malignant progression of clear cell renal cell carcinoma. January 28, 2022

Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor. January 28, 2022

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery January 27, 2022

Pyroptosis Regulators and Tumor Microenvironment Infiltration Characterization in Clear Cell Renal Cell Carcinoma. January 27, 2022

Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists. January 27, 2022

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. January 26, 2022

Association of Extrarenal Invasion Patterns and Tumor Size with the Differences in Survival Outcomes of T3a Renal Cell Carcinoma: A Proposal Modified T3a Stage System is Needed. January 26, 2022

Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response. January 25, 2022

High efficiency capture of biomarker miRNA15a for noninvasive diagnosis of malignant kidney tumors. January 25, 2022

Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy? January 24, 2022

The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy. January 24, 2022

Page 83 of 456